News & Updates

Adding durvalumab upfront to chemo ups long-term survival in SCLC

Patients were threefold more likely to survive long term (beyond 3 years) when durvalumab was added to first-line chemotherapy, with or without tremelimumab, compared with those on chemotherapy alone, according to a post hoc analysis of long-term survivors (LTS) with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study.

No COVID-19 cases in cancer patients 1-year post-vax

There are no COVID-19 cases documented in patients with solid tumours at 1-year post-vaccination with the BNT162b2 vaccine as shown in a prospective study from Israel.

Working out cuts risk of developing aggressive breast cancer

CV risk elevated following cancer diagnosis

Patients newly diagnosed with cancer have an increased risk of cardiovascular (CV) events including CV mortality, according to a retrospective population-based study from Canada.

Should intraperitoneal chemo be reconsidered for ovarian cancer?

Progression-free survival (PFS) is significantly longer with intraperitoneal (IP) over intravenous (IV) carboplatin, when combined with dose-dense paclitaxel, in patients with ovarian, fallopian tube, or primary peritoneal cancer, regardless of residual tumour size after initial surgery, according to the phase III iPocc* trial presented at SGO 2022.